EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Clinical trials for EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a DNA-Repair blocker boost chemo in tough lung cancer?
Disease control OngoingThis study tests whether adding the experimental drug berzosertib to standard chemotherapy (topotecan) helps people with small cell lung cancer that has returned after initial treatment. About 104 participants will receive either the combo or topotecan alone. The goal is to see i…
Matched conditions: EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:43 UTC
-
New combo aims to boost chemo for tough lung cancer
Disease control OngoingThis early-phase study tests a new drug (LB-100) added to standard chemotherapy and immunotherapy for people with untreated extensive-stage small cell lung cancer. The goal is to find the safest dose and see if the combination helps shrink tumors. Only 3 participants were enrolle…
Matched conditions: EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 09:43 UTC
-
Triple-Drug attack aims to shrink returned lung cancer
Disease control OngoingThis early-phase trial tests a three-drug combination for small cell lung cancer that has come back after treatment. The drugs include a targeted therapy (tazemetostat), a chemotherapy (topotecan), and an immunotherapy (pembrolizumab). The goal is to find the safest dose and see …
Matched conditions: EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:34 UTC
-
New combo aims to stall aggressive lung cancer
Disease control OngoingThis study tests whether adding talazoparib to atezolizumab works better than atezolizumab alone to keep extensive-stage small cell lung cancer from growing. About 103 adults with a specific genetic marker (SLFN11-positive) will receive one of the two treatments as maintenance th…
Matched conditions: EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:33 UTC
-
Triple-Drug cocktail shows promise for tough lung cancers
Disease control OngoingThis study tests a combination of three drugs (niraparib, temozolomide, and atezolizumab) in people with advanced solid tumors or extensive-stage small cell lung cancer that responded to initial chemotherapy. The goal is to find the safest dose and see if the combo helps keep can…
Matched conditions: EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 09:32 UTC
-
New drug cocktail shows promise against aggressive lung cancer
Disease control OngoingThis study tests a new treatment combination for people with extensive-stage small cell lung cancer (ES-SCLC) who haven't had treatment yet. It combines a PARP inhibitor (olaparib), an immunotherapy drug (durvalumab), standard chemotherapy (carboplatin and etoposide), and radiati…
Matched conditions: EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:57 UTC